摘要:
Erfindungsgemäß wurden Tumor-assoziiert exprimierte Genprodukte und die dafür kodierenden Nukleinsäuren identifiziert. Die vorliegende Erfindung betrifft die Therapie und Diagnose von Erkrankungen, bei denen diese Tumor-assoziiert exprimierten Genprodukte aberrant exprimiert werden. Des Weiteren betrifft die Erfindung Proteine, Polypeptide und Peptide, die Tumor-assoziiert exprimiert werden und die dafür kodierenden Nukleinsäuren.
摘要翻译:药物组合物含有限制与肿瘤相关的抗原的表达或活性的药剂。 抗原具有由核酸编码的序列,其中核酸或序列来自SEQ ID NO:19-21,54-57,1-5,29,31-33,37,39,40 ,62,63,70,74,85-88作为部分或衍生物。 它还具有在严格条件下与核酸/序列组杂交的核酸,被退化的核酸和互补核酸。
摘要:
The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor- associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
摘要:
The present invention relates to efficient methods for providing antigen- specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
摘要:
The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.